🇺🇸 FDA
Patent

US 9228188

Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression

granted A61KA61K31/7105A61K33/26

Quick answer

US patent 9228188 (Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression) held by Alnylam Pharmaceuticals, Inc. expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/7105, A61K33/26, A61K47/549